At the same time, China’s gross national income per capita has grown more than ten-fold since 2000, reaching $11,880 in 20212. And this newly affluent middle class is placing greater emphasis on health and wellbeing. Younger generations in particular desire healthier lifestyles. Many are willing and able to pay for preventive measures to protect themselves. This has led to a growth in specialist care, high-tech devices, and top-end therapies.
Given all these factors, it’s no wonder investors are increasingly taking notice of the Chinese healthcare system. For our part, we’re finding investment opportunities across sectors and the market-cap scale.
How does this look in practice?
For a doctor, a good bedside manner makes all the difference. In the past, however, many Chinese hospitals suffered from a lack of investment and a paucity of trained staff. Service was poor. Happily, the situation is improving thanks to companies like Aier Eye Hospitals.
As China’s largest private eyecare operator, it knows that quality doctors are a key to success. That’s why it offers incentives to attract and retain quality staff. It also provides university tuition courses, helping cultivate the healthcare professionals of tomorrow. Aier’s services are affordable and, as a result, receive tacit government approval as valuable and necessary. The company is also well-placed to benefit from China’s rising wealth. The doctor will see you now.
China’s medical device market is dominated by foreign players. There are signs, though, that this is changing. The US/China trade war that started in 2018 meant many Chinese healthcare companies had to look inward to develop their own products. Meanwhile, the Covid-19 pandemic and associated lockdowns underlined the need for improved self-sufficiency in numerous sectors, including healthcare.
This newly affluent middle class is placing greater emphasis on health and wellbeing
Enter Mindray. It designs and produces medical equipment and accessory for both human and veterinary use. It has three main businesses: patient monitoring & life support, in-vitro diagnostics, and medical imaging systems. It’s one of the many Chinese companies underpinning the roadmap to localisation, while seeking to gain overseas market share. New products and its ongoing platform business model (design, distribution, R&D, cross-selling) should help drive the company’s long-term growth outlook.
Clinical research is the backbone of medicine. Through research, companies gain vital insights into the effectiveness of drugs, therapies, and devices. It also ensures products are safe. Research is big business, too. One company to highlight here is Tigermed, one of the country’s leading domestic contract research organisations. It mainly conducts phase I-V clinical trials for the biopharmaceutical and medical device industry. The company has a long track record of delivering quality service, with a large, experienced employee base. What’s more, customers need consistency and so stick around when the service is good. This gives consistency to Tigermed’s earnings. Meanwhile, recent reforms should also see R&D spending ramp up on innovative drugs. This could be a boon for companies like Tigermed.
What’s the long-term outlook?
The Chinese healthcare system is huge and growing. China’s National Health and Family Planning Commission aims to expand the size of the country’s health service sector to around US$2.4 trillion by 2030. The number of people aged over 60 is set to double to 324 million by 2027. The equivalent to the population of the US. At the same time, disposable incomes are growing. Companies that can cater to this rising demand, should be in line to make healthy profits.
Companies are selected for illustrative purposes only to demonstrate the investment management style described herein and not as an investment recommendation or indication of future performance. Past performance is not a guide to future results.
1Worldmeter 2023
2Macrotrends 2022
3Businesswire July 2022